Cargando…

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies

Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as im...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivares-Hernández, Alejandro, Figuero-Pérez, Luis, Terán-Brage, Eduardo, López-Gutiérrez, Álvaro, Velasco, Álvaro Tamayo, Sarmiento, Rogelio González, Cruz-Hernández, Juan Jesús, Miramontes-González, José Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124332/
https://www.ncbi.nlm.nih.gov/pubmed/33925214
http://dx.doi.org/10.3390/jcm10091919
_version_ 1783693173680242688
author Olivares-Hernández, Alejandro
Figuero-Pérez, Luis
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Velasco, Álvaro Tamayo
Sarmiento, Rogelio González
Cruz-Hernández, Juan Jesús
Miramontes-González, José Pablo
author_facet Olivares-Hernández, Alejandro
Figuero-Pérez, Luis
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Velasco, Álvaro Tamayo
Sarmiento, Rogelio González
Cruz-Hernández, Juan Jesús
Miramontes-González, José Pablo
author_sort Olivares-Hernández, Alejandro
collection PubMed
description Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.
format Online
Article
Text
id pubmed-8124332
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81243322021-05-17 Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies Olivares-Hernández, Alejandro Figuero-Pérez, Luis Terán-Brage, Eduardo López-Gutiérrez, Álvaro Velasco, Álvaro Tamayo Sarmiento, Rogelio González Cruz-Hernández, Juan Jesús Miramontes-González, José Pablo J Clin Med Review Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice. MDPI 2021-04-28 /pmc/articles/PMC8124332/ /pubmed/33925214 http://dx.doi.org/10.3390/jcm10091919 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Olivares-Hernández, Alejandro
Figuero-Pérez, Luis
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Velasco, Álvaro Tamayo
Sarmiento, Rogelio González
Cruz-Hernández, Juan Jesús
Miramontes-González, José Pablo
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title_full Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title_fullStr Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title_full_unstemmed Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title_short Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
title_sort resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: a new therapeutic targeting of haematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124332/
https://www.ncbi.nlm.nih.gov/pubmed/33925214
http://dx.doi.org/10.3390/jcm10091919
work_keys_str_mv AT olivareshernandezalejandro resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT figueroperezluis resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT teranbrageeduardo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT lopezgutierrezalvaro resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT velascoalvarotamayo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT sarmientorogeliogonzalez resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT cruzhernandezjuanjesus resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies
AT miramontesgonzalezjosepablo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies